1-7 of 7
Carlos Flores
Close
Sort by
Journal Articles

Real-World Outcomes in Relapsed/Refractory DLBCL Patients Who Received Polatuzumab Vedotin PLUS Bendamustine and Rituximab or Tafasitamab Plus Lenalidomide By Line of Therapy

Mehdi Hamadani, Laura Liao, Lauren Wilson, Amanda Howarth, Carlos Flores, Lei Chen
Journal: Blood
Blood (2022) 140 (Supplement 1): 8058–8060.
https://doi.org/10.1182/blood-2022-167753
Published: 2022
Journal Articles

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Physician First-Line Treatment Preferences for Stage III or IV Classical Hodgkin Lymphoma

Andrew M. Evens, Kristina S. Yu, Nicholas Liu, Andy Surinach, Katie Holmes, Carlos Flores, Supriya Kumar, Michelle A. Fanale, Darcy R. Flora, Susan K. Parsons
Journal: Blood
Blood (2021) 138 (Supplement 1): 2467.
https://doi.org/10.1182/blood-2021-152497
Published: 2021
Journal Articles

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT): Observations of Physicians on Treatment and Interim PET-Adapted Regimens

Susan K. Parsons, Kristina S. Yu, Nicholas Liu, Supriya Kumar, Michelle A. Fanale, Katie Holmes, Carlos Flores, Andy Surinach, Darcy R. Flora, Andrew M. Evens
Journal: Blood
Blood (2021) 138 (Supplement 1): 1390.
https://doi.org/10.1182/blood-2021-151143
Published: 2021
Journal Articles

Classical Hodgkin Lymphoma; Real-World Observations from Physicians, Patients, and Caregivers on the Disease and Its Treatment (CONNECT)-a Cross-Sectional Survey of Patients with Stage III or IV Classical Hodgkin Lymphoma Compared By Age

Darcy R. Flora, Susan K. Parsons, Nicholas Liu, Kristina S. Yu, Katie Holmes, Carlos Flores, Michelle A. Fanale, Supriya Kumar, Andy Surinach, Rachel Byrd, Andrew M. Evens
Journal: Blood
Blood (2021) 138 (Supplement 1): 1966.
https://doi.org/10.1182/blood-2021-147354
Published: 2021
Journal Articles

Real-World Characteristics of Patients with Classical Hodgkin Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

Tycel J. Phillips, MD, Kristina Yu-Isenberg, PhD MPH, RPh, Nicholas Liu, PharmD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Michelle A. Fanale, MD, John M. Burke, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 3–4.
https://doi.org/10.1182/blood-2020-140534
Published: 2020
Journal Articles

Real-World Characteristics of Patients with Peripheral T-Cell Lymphoma Receiving Frontline Brentuximab Vedotin with Chemotherapy: A Retrospective Analysis with Propensity Score Matching

John M. Burke, MD, Nicholas Liu, PharmD, Kristina Yu-Isenberg, PhD MPH, RPh, Michelle A. Fanale, MD, Andy Surinach, MPH, Carlos Flores, MPH, Julie Lisano, PharmD, Tycel J. Phillips, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 18–19.
https://doi.org/10.1182/blood-2020-140832
Published: 2020
Journal Articles

Estimating the Risk of Myocardial Infarction in Persons with Hemophilia A Using a Machine-Learning Approach with US Claims Data

Imi Faghmous, MPH, Carlos Flores, MPH, Kati Sarouei, MD, Tiffany Y. Chang, MD MAS, Anisha M. Patel, PhD, Cami S. Sima, MD, Peter Kuebler, PharmD
Journal: Blood
Blood (2019) 134 (Supplement_1): 1133.
https://doi.org/10.1182/blood-2019-123761
Published: 2019